Endonovo Therapeutics (OTCMKTS:ENDV – Get Rating) and InMode (NASDAQ:INMD – Get Rating) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, dividends, profitability, valuation, earnings, institutional ownership and risk.
Volatility & Risk
Endonovo Therapeutics has a beta of 0.18, suggesting that its share price is 82% less volatile than the S&P 500. Comparatively, InMode has a beta of 2.08, suggesting that its share price is 108% more volatile than the S&P 500.
Analyst Ratings
This is a breakdown of current ratings and recommmendations for Endonovo Therapeutics and InMode, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Endonovo Therapeutics | 0 | 0 | 0 | 0 | N/A |
| InMode | 0 | 1 | 5 | 0 | 2.83 |
Earnings & Valuation
This table compares Endonovo Therapeutics and InMode’s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Endonovo Therapeutics | $140,000.00 | 25.10 | -$18.48 million | N/A | N/A |
| InMode | $454.27 million | 6.24 | $161.52 million | $2.01 | 16.97 |
InMode has higher revenue and earnings than Endonovo Therapeutics.
Profitability
This table compares Endonovo Therapeutics and InMode’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Endonovo Therapeutics | -3,988.29% | N/A | -639.23% |
| InMode | 36.05% | 36.35% | 31.88% |
Insider and Institutional Ownership
55.2% of InMode shares are owned by institutional investors. 5.6% of Endonovo Therapeutics shares are owned by insiders. Comparatively, 6.9% of InMode shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Summary
InMode beats Endonovo Therapeutics on 10 of the 11 factors compared between the two stocks.
About Endonovo Therapeutics
Endonovo Therapeutics, Inc. is a biotechnology company, which engages in the development, manufacture, and distribution of medical devices focused on the rapid healing of wounds and reduction of pain, edema, and inflammation on and in the human body. Its technology and products include Electroceuticals, EFECT Trial, and SofPulse Electroceutical Therapy. The company was founded in November 2008 and is headquartered in Woodland Hills, CA.
About InMode
InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures. It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions, as well as hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. InMode Ltd. was incorporated in 2008 and is headquartered in Yokneam, Israel.
Receive News & Ratings for Endonovo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endonovo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
